Nanoinformatics and Personalized Medicine: An Advanced Cumulative Approach for Cancer Management

被引:5
作者
Khan, Fariya [1 ]
Akhtar, Salman [1 ,2 ,8 ]
Kamal, Mohammad Amjad [3 ,4 ,5 ,6 ,7 ]
机构
[1] Integral Univ, Fac Engn, Dept Bioengn, Lucknow 226026, UP, India
[2] Novel Global Community Educ Fdn, Hebersham, NSW 2770, Australia
[3] Sichuan Univ, West China Hosp, Inst Syst Genet, Frontier Sci Ctr Dis Related Mol Network, Chengdu, Peoples R China
[4] King Abdulaziz Univ, King Fahad Med Res Ctr, Jeddah 21589, Saudi Arabia
[5] Daffodil Int Univ, Fac Allied Hlth Sci, Dept Pharm, Dhaka 1207, Bangladesh
[6] Enzymoics, 7 Peterlee Pl, Hebersham, NSW 2770, Australia
[7] Novel Global Community Educ Fdn, Hebersham, Australia
[8] Integral Univ, Fac Engn, Dept Bioengn, Lucknow 226026, India
关键词
Personalized medicine; oncogenomics; nanomedicine; nanoinformatics; cancer informatics; bioinformatics; ENDOTHELIAL GROWTH-FACTOR; KRAS MUTATIONS; POLYMORPHISMS; INHIBITORS; TAMOXIFEN; ASSAYS; TIME;
D O I
10.2174/0929867329666220610090405
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background Even though the battle against one of the deadliest diseases, cancer, has advanced remarkably in the last few decades and the survival rate has improved significantly; the search for an ultimate cure remains a utopia. Nanoinformatics, which is bioinformatics coupled with nanotechnology, endows many novel research opportunities in the preclinical and clinical development of personalized nanosized drug carriers in cancer therapy. Personalized nanomedicines serve as a promising treatment option for cancer owing to their noninvasiveness and their novel approach. Explicitly, the field of personalized medicine is expected to have an enormous impact soon because of its many advantages, namely its versatility to adapt a drug to a cohort of patients. Objective The current review explains the application of this newly emerging field called nanoinformatics to the field of precision medicine. This review also recapitulates how nanoinformatics could hasten the development of personalized nanomedicine for cancer, which is undoubtedly the need of the hour. Conclusion This approach has been facilitated by a humongous impending field named Nanoinformatics. These breakthroughs and advances have provided insight into the future of personalized medicine. Imperatively, they have been enabling landmark research to merge all advances, creating nanosized particles that contain drugs targeting cell surface receptors and other potent molecules designed to kill cancerous cells. Nanoparticle-based medicine has been developing and has become a center of attention in recent years, focusing primely on proficient delivery systems for various chemotherapy drugs.
引用
收藏
页码:271 / 285
页数:15
相关论文
共 52 条
[1]   V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours [J].
Agaimy, A. ;
Terracciano, L. M. ;
Dirnhofer, S. ;
Tornillo, L. ;
Foerster, A. ;
Hartmann, A. ;
Bihl, M. P. .
JOURNAL OF CLINICAL PATHOLOGY, 2009, 62 (07) :613-616
[2]   Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].
Amado, Rafael G. ;
Wolf, Michael ;
Peeters, Marc ;
Van Cutsem, Eric ;
Siena, Salvatore ;
Freeman, Daniel J. ;
Juan, Todd ;
Sikorski, Robert ;
Suggs, Sid ;
Radinsky, Robert ;
Patterson, Scott D. ;
Chang, David D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634
[3]   SRD5A Polymorphisms and Biochemical Failure After Radical Prostatectomy [J].
Audet-Walsh, Etienne ;
Bellemare, Judith ;
Nadeau, Genevieve ;
Lacombe, Louis ;
Fradet, Yves ;
Fradet, Vincent ;
Huang, Shu-Pin ;
Bao, Bo-Ying ;
Douville, Pierre ;
Girard, Hugo ;
Guillemette, Chantal ;
Levesque, Eric .
EUROPEAN UROLOGY, 2011, 60 (06) :1226-1234
[4]   Regulatory BCL2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma [J].
Bachmann, Hagen S. ;
Heukamp, Lukas C. ;
Schmitz, Klaus J. ;
Hilburn, Caroline F. ;
Kahl, Philip ;
Buettner, Reinhard ;
Nueckel, Holger ;
Eisenhardt, Andreas ;
Ruebben, Herbert ;
Schmid, Kurt Werner ;
Siffert, Winfried ;
Eggert, Angelika ;
Schramm, Alexander ;
Schulte, Johannes H. .
INTERNATIONAL JOURNAL OF CANCER, 2011, 129 (10) :2390-2399
[5]  
Baker N.A., 2009, CABIG INTEGRATIVE CA
[6]  
Bawa R., 2016, CLIN NANOMEDICINE
[7]   Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan [J].
Boni, V. ;
Zarate, R. ;
Villa, J. C. ;
Bandres, E. ;
Gomez, M. A. ;
Maiello, E. ;
Garcia-Foncillas, J. ;
Aranda, E. .
PHARMACOGENOMICS JOURNAL, 2011, 11 (06) :429-436
[8]   Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: The 'personalised' approach? [J].
Brauch, Hiltrud ;
Jordan, V. Craig .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (13) :2274-2283
[9]   Increased Expression of Vascular Endothelial Growth Factor and Its Receptors, VEGFR-1 and VEGFR-2, in Medullary Thyroid Carcinoma [J].
Capp, Clarissa ;
Wajner, Simone Magagnin ;
Siqueira, Debora Rodrigues ;
Brasil, Beatriz Assis ;
Meurer, Luise ;
Maia, Ana Luiza .
THYROID, 2010, 20 (08) :863-871
[10]   Methylenetetrahydrofolate Reductase Polymorphism (677 C > T) Predicts Long Time to Progression in Metastatic Colon Cancer Treated with 5-Fluorouracil and Folinic Acid [J].
Castillo-Fernandez, Omar ;
Santibanez, Miguel ;
Bauza, Aldo ;
Calderillo, German ;
Castro, Clementina ;
Herrera, Roberto ;
Serrano, Alberto ;
Arrieta, Oscar ;
Herrera, Luis A. .
ARCHIVES OF MEDICAL RESEARCH, 2010, 41 (06) :430-435